In the last trading session, 1.06 million shares of the C4 Therapeutics Inc (NASDAQ:CCCC) were traded, and its beta was 3.01. Most recently the company’s share price was $2.38, and it changed around -$0.02 or -0.83% from the last close, which brings the market valuation of the company to $168.96M. CCCC currently trades at a discount to its 52-week high of $11.88, offering almost -399.16% off that amount.
C4 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.80. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended CCCC as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. C4 Therapeutics Inc is expected to report earnings per share of -0.42 for the current quarter.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC has showed a red trend with a performance of -0.83% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.83 on recent trading dayincreased the stock’s daily price by 15.9%. The company’s shares are currently down -33.89% year-to-date, but still down -14.70% over the last five days. On the other hand, C4 Therapeutics Inc (NASDAQ:CCCC) is -31.41% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 85.12% from its current value. Analyst projections state that CCCC is forecast to be at a low of $12 and a high of $20.
C4 Therapeutics Inc (CCCC) estimates and forecasts
The year-over-year growth rate is expected to be -39.60%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 2.95M in revenue for the current quarter. 6 analysts expect C4 Therapeutics Inc to make 4.43M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.04M and 12.01M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -2.93%. Forecasts for the next quarter put sales growth at -63.07%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -8.92%. C4 Therapeutics Inc earnings are expected to increase by -21.75% in 2025, but the outlook is negative -1.62% per year for the next five years.
CCCC Dividends
C4 Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
RA CAPITAL MANAGEMENT, L.P., with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.38 shares worth $8.05 million, making up 4.77% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.14 shares worth around $5.08 million, which represents about 3.01% of the total shares outstanding.
